SCHWEIZ - WÄHLEN SIE EIN LAND  Presse  Transparenz und Partnerschaften
rheum-grant-logo


Award description

The AbbVie Rheumatology Grant supports one study per year.

Award & EULAR 2019: The winner will receive 50’000.– CHF (excl. VAT) for the submitted project and a EULAR 2019 congress invitation to Madrid.

This award will be remitted to the institution account, after announcement of the selected project.

Project selection: According to the criteria defined by the AbbVie ¬Rheumatology Grant Jury Board.


Timelines

Participants have to complete the concept submission form available on

www.rheuma-net.ch

and submit their complete application to the Jury president and AbbVie by 30th April 2018 via E-Mail:

paul.hasler@ksa.ch and martin.schulz@abbvie.com

Only formally complete submissions will be considered by the Jury. Any potential issues must be fully addressed by the applicant before the deadline.

Announcement of the winner at the SGR/SGAI Congress

in Interlaken, 30th– 31st August 2018.


Criteria & Obligations 

....for applicants
 

Applicant (or co-applicant) has to be a physician.

Age & Career Status: 45 years or less. The AbbVie Rheumatology Grant is addressing young scientists. Therefore, candidates with established academic ­careers (e.g. Professors) are excluded. 

Location: The principal investigator and his/her study center have to be located in Switzerland.

A collaboration with other investigators and/or other centers (inside or outside of Switzerland) is allowed and has to be specified in the application.

....for the submission
 

Research fields: Clinical and/or basic oriented research in rheumatology and/or in the field of clinical immunology, the planned study must have relevance for patient care.

Written consent: Date and signature from the applicant and the Head of the Department or Institution where the project is planned to be ¬conducted are ¬required.

Responsibilities: The principal investigator is responsible for the project and all legal permissions (ethic committee, Swissmedic notification, insurance, etc.).

Follow-up: The winner of the grant will present the research project, as well as the final data, at the scientific session of the following SGR/SGAI Congress. The winner will provide an annual report about the development to the President of the Jury Board until finalization of the research project.

Legal form: Investigator driven study according to GCP and/or GLP.

Study design: Prospective or retrospective.

Status of the project: New research projects or ongoing projects.


Jury board

   
President:      Prof. Paul Hasler, Aarau
   
Vice-president: Prof. Axel Finckh, Genève
   
Members:

Prof. Oliver Distler, Zürich

Prof. Thomas Hügle, Lausanne

Prof. Johannes v. Kempis, St. Gallen

Prof. Diego Kyburz, Basel

Prof. Peter Villiger, Bern

   

Verlassen abbvie.ch

Die von Ihnen angeforderte AbbVie-Internetseite ist nur für bestimmte Länder vorgesehen. (Entsprechende Hinweise finden Sie auf der Seite.) Daher kann die Website Informationen zu Arzneimitteln, anderen Produkten oder zur Verwendungen dieser Produkte enthalten, die in anderen Ländern oder Regionen nicht zugelassen sind. Sollte Letzteres für Sie zutreffen, wenden Sie sich bitte an Ihre AbbVie Landesgesellschaft, um die richtigen Produktinformationen für Ihr Land zu erhalten.

Die von Ihnen angeforderte AbbVie-Internetseite ist nicht in deutscher Sprache.

Die AbbVie-Internetseite, die Sie angefordert haben, ist möglicherweise nicht für Ihre Bildschirmgröße optimiert.

Möchten Sie fortfahren?

Wichtiger Hinweis

Sie verlassen jetzt die Webseite der AbbVie Schweiz und somit unseren Zuständigkeitsbereich. Die verlinkten Seiten besitzen eigene Nutzungsbedingungen und unterliegen möglicherweise anderen Gesetzgebungen und Datenschutzbestimmungen.